SOURCE: XenaCare Holdings, Inc.

XenaCare Holdings, Inc.

May 20, 2010 08:27 ET

XenaCare to Attend National Association of Chain Drug Stores (NACDS) MarketPlace Conference in San Diego June 5th-9th

DELRAY BEACH, FL--(Marketwire - May 20, 2010) -  XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it will be attending the National Association of Chain Drug Stores (NACDS) MarketPlace Conference in San Diego from June 5th to June 9th.

NACDS represents the largest component of pharmacy practice -- chain community pharmacies. Its members comprise one of the fastest growing and most dynamic segments of America's retail community and are an essential component of the healthcare system.

"We are looking forward to participating in this incredible conference especially 'Meet The Market' on Saturday, where we'll have an opportunity to meet individual buyers one-on-one as well as three additional days where buyers meet with us in our booth," said Frank Rizzo, President of XenaCare.

The NACDS MarketPlace Conference is the largest and most powerful convergence of drug, food, mass, club, and value retailing in the United States, if not the world. Over 400 manufacturer and service companies participate in this appointment-oriented show.

MarketPlace represents more than 90 percent of the industry, bringing together more than 250 retail companies representing over 145,000 retail outlets and over $500 billion in annual buying power. In a phrase, MarketPlace is the lifeblood of the industry. It is a venue for retail buyers and sellers to meet one another and work together to bring new and innovative products to market.

About XenaCare Holdings
XenaCare Holdings, Inc. engages in the branding, formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain, the Company's clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body's oxygen carrying capacities designed to support digestion. XenaCare's clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in XenaCare's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information

  • Contact:
    XenaCare Holdings
    Frank Rizzo
    Email Contact